Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - Micardis Plus(R) - Klinische Wirksamkeit (39 Abbildungen)
Übersicht


Zum ersten Bild Abb. 13: Telmisartan - Valsartan Abb. 14: Telmisartan - Valsartan Abb. 15: Telmisartan - Valsartan Aktuelles Bild - Abb. 16: Telmisartan - Ramipril Abb. 17: Telmisartan - Ramipril Abb. 18: Morgendlicher Blutdruckanstieg Abb. 19: Telmisartan - Perindopril Zum letzten Bild
Abbildung 16: Telmisartan - Ramipril
Telmisartan 80 mg provides superior reductions in SBP and DBP in the last 6 h of the dosing interval compared with ramipril 10 mg. Data shown are from two independent, fixed-dose, 14-week studies: Prospective, Randomized Investigation of the Safety and efficacy of Micardis versus ramipril using ABPM (PRISMA) I and II. PRISMA I was conducted in Europe and South Africa, and recruited 801 patients.1 PRISMA II was conducted in the USA and Canada, and recruited 812 patients.2 Patients were started on telmisartan 40 mg or ramipril 2.5 mg, and force titrated to telmisartan 80 mg or ramipril 5 mg after 2 weeks. At Week 8, ramipril was further up titrated to 10 mg. Blood pressure was measured using ABPM. As well as superiority in the early morning period, in both studies telmisartan was significantly superior to ramipril over the 24-h mean and other time periods: morning (06:00–11:59), daytime (06:00–21:59), and night-time (22:00–05:59). 1. Williams B, et al. Superior blood pressure reduction in the last 6 h of the dosing interval with once-daily telmisartan versus ramipril. Hypertension 2004; 44: 576. 2. Lacourcière Y, et al. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. Hypertension 2004; 44: 576.
 
Telmisartan - Ramipril
Vorheriges Bild Nächstes Bild   


Abbildung 16: Telmisartan - Ramipril
Telmisartan 80 mg provides superior reductions in SBP and DBP in the last 6 h of the dosing interval compared with ramipril 10 mg. Data shown are from two independent, fixed-dose, 14-week studies: Prospective, Randomized Investigation of the Safety and efficacy of Micardis versus ramipril using ABPM (PRISMA) I and II. PRISMA I was conducted in Europe and South Africa, and recruited 801 patients.1 PRISMA II was conducted in the USA and Canada, and recruited 812 patients.2 Patients were started on telmisartan 40 mg or ramipril 2.5 mg, and force titrated to telmisartan 80 mg or ramipril 5 mg after 2 weeks. At Week 8, ramipril was further up titrated to 10 mg. Blood pressure was measured using ABPM. As well as superiority in the early morning period, in both studies telmisartan was significantly superior to ramipril over the 24-h mean and other time periods: morning (06:00–11:59), daytime (06:00–21:59), and night-time (22:00–05:59). 1. Williams B, et al. Superior blood pressure reduction in the last 6 h of the dosing interval with once-daily telmisartan versus ramipril. Hypertension 2004; 44: 576. 2. Lacourcière Y, et al. A prospective, randomized investigation of the safety and efficacy of telmisartan vs ramipril in mild-to-moderate hypertensives using ambulatory blood pressure monitoring. Hypertension 2004; 44: 576.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung